{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:13:18Z","timestamp":1793041998636,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2026.106083","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:42:49Z","timestamp":1772559769000},"page":"106083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1276-3289","authenticated-orcid":false,"given":"J.","family":"Hadoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-7360","authenticated-orcid":false,"given":"J.","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-3921","authenticated-orcid":false,"given":"K.H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5027-7660","authenticated-orcid":false,"given":"H.","family":"Lasolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Buffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Benisvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5676-0127","authenticated-orcid":false,"given":"F.","family":"Illouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Schneegans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3357-6914","authenticated-orcid":false,"given":"R.","family":"Varnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4579-4129","authenticated-orcid":false,"given":"D.","family":"Drui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2002-0255","authenticated-orcid":false,"given":"S.","family":"Zanetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Roudaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-3666","authenticated-orcid":false,"given":"M.","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6484-1365","authenticated-orcid":false,"given":"R.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4913-0892","authenticated-orcid":false,"given":"W.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-6361","authenticated-orcid":false,"given":"I.","family":"Borget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-7633","authenticated-orcid":false,"given":"G.","family":"Segall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2026.106083_bib1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1210\/endrev\/bnad013","article-title":"Medullary thyroid cancer: updates and challenges","volume":"44","author":"Gild","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.esmoop.2026.106083_bib2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106083_bib3","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106083_bib4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106083_bib5","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106083_bib6","series-title":"CAPRELSA\u00ae (vandetanib) tablets, for oral use","year":"2022"},{"key":"10.1016\/j.esmoop.2026.106083_bib7","series-title":"COMETRIQ\u00ae (cabozantinib) capsules, for oral use","year":"2023"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106083_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.esmoop.2026.106083_bib9","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106083_bib10","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106083_bib11","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2026.106083_bib12","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106083_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000445978","article-title":"Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma","volume":"90","author":"Heilmann","year":"2016","journal-title":"Oncology"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106083_bib14","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1111\/bph.14395","article-title":"Drug resistance profiles of mutations in the RET kinase domain","volume":"175","author":"Liu","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.esmoop.2026.106083_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET-altered thyroid cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2026.106083_bib16","doi-asserted-by":"crossref","first-page":"S1299","DOI":"10.1016\/j.annonc.2022.07.1736","article-title":"1656P Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): update of the LIBRETTO-001 trial","volume":"33","author":"Kroiss","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106083_bib17","series-title":"RETEVMO\u00ae (selpercatinib) capsules, for oral use. Prescribing information","year":"2024"},{"key":"10.1016\/j.esmoop.2026.106083_bib18","series-title":"RETSEVMO\u00ae (selpercatinib) capsules, for oral use. Summary of product characteristics","year":"2024"},{"issue":"27","key":"10.1016\/j.esmoop.2026.106083_bib20","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106083_bib22","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s43441-021-00302-y","article-title":"The use of external controls in FDA regulatory decision making","volume":"55","author":"Jahanshahi","year":"2021","journal-title":"Ther Innov Regul Sci"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106083_bib23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jval.2021.01.015","article-title":"Use of external comparators for health technology assessment submissions based on single-arm trials","volume":"24","author":"Patel","year":"2021","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106083_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.annonc.2021.12.015","article-title":"External control arms in oncology: current use and future directions","volume":"33","author":"Mishra-Kalyani","year":"2022","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2026.106083_bib25","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1182\/bloodadvances.2022009167","article-title":"Enriching single-arm clinical trials with external controls: possibilities and pitfalls","volume":"7","author":"Lambert","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.esmoop.2026.106083_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114261","article-title":"Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database","volume":"209","author":"Mortier","year":"2024","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjebm-2022-112091","article-title":"Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health","volume":"29","author":"Vanier","year":"2024","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.esmoop.2026.106083_bib28","article-title":"Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process","volume":"27","author":"Zisis","year":"2024","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106083_bib29","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/pds.5141","article-title":"Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials","volume":"29","author":"Seeger","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106083_bib30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40264-020-00944-1","article-title":"A framework for methodological choice and evidence assessment for studies using external comparators from real-world data","volume":"43","author":"Gray","year":"2020","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13044-021-00119-9","article-title":"Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced\/metastatic medullary thyroid cancer","volume":"15","author":"Parikh","year":"2022","journal-title":"Thyroid Res"},{"key":"10.1016\/j.esmoop.2026.106083_bib32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials \u2013 a primer for researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.esmoop.2026.106083_bib34","article-title":"Considerations for the design and conduct of externally controlled trials for drug and biological products","year":"2023","journal-title":"Guidance for industry"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/pan\/mpr025","article-title":"Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies","volume":"20","author":"Hainmueller","year":"2012","journal-title":"Polit Anal"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12874-025-02481-w","article-title":"Propensity score matching: should we use it in designing observational studies?","volume":"25","author":"Wan","year":"2025","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106083_bib38","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jamaoncol.2024.3466","article-title":"Externally controlled studies using real-world data in patients with hematological cancers: a systematic review","volume":"10","author":"Hermans","year":"2024","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106083_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2024.03.2420","article-title":"MSR105 Proportional randomization method to identify index line of therapy in externally controlled trials","volume":"27","author":"Cui","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib42","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0172","article-title":"Real-world clinical profile, RET mutation testing, treatments, and PROs for MTC in Europe","volume":"13","author":"Segall","year":"2024","journal-title":"Eur Thyroid J"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2026.106083_bib43","first-page":"A-3","article-title":"Efficacy of selpercatinib by RET mutation in RET-mutant medullary thyroid cancer: a combined analysis of LIBRETTO-001 and LIBRETTO-531 trials","volume":"34","author":"Hadoux","year":"2024","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.21.01329","article-title":"International Medullary Thyroid Carcinoma Grading System: a validated grading system for medullary thyroid carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106083_bib45","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/10507256251388028","article-title":"Validation of the International Medullary Thyroid Carcinoma Grading System in patients with distant metastases","volume":"35","author":"Porcelli","year":"2025","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106083_bib46","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106083_bib47","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib48","first-page":"25","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharmaceut Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106083_bib49","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s11096-023-01591-z","article-title":"Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework","volume":"45","author":"Shafei","year":"2023","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jval.2024.09.007","article-title":"A review and comparative case study analysis of real-world evidence in European regulatory and health technology assessment decision making for oncology medicines","volume":"28","author":"Zong","year":"2025","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.2766","article-title":"Contribution of real-world evidence in European Medicines Agency\u2019s regulatory decision making","volume":"113","author":"Bakker","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106083_bib52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.2474","article-title":"The role of real-world evidence in FDA-approved new drug and biologics license applications","volume":"111","author":"Purpura","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106083_bib53","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jval.2020.06.006","article-title":"Use of real-world evidence to support FDA approval of oncology drugs","volume":"23","author":"Feinberg","year":"2020","journal-title":"Value Health"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:14:24Z","timestamp":1774487664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702926000256"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106083","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106083"}}